Arcturus to Report Corporate Overview and Financial Results on August 15
August 07, 2019 07:00 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
August 02, 2019 14:00 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of...
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
August 01, 2019 12:30 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of...
Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients
August 01, 2019 12:10 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation (CF...
Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference
July 10, 2019 09:00 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
June 27, 2019 16:01 ET
|
Arcturus Therapeutics Holdings Ltd
SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics...
Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation
June 13, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, June 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
May 20, 2019 11:02 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, May 20, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and...
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update
May 13, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of...
Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results
March 18, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of...